stockrow
Friday 6 November 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
26.82
1.03
+3.99%
Follow VKTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
7.27 | 4.72 | 5.72 | 9.33 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.78 | 3.76 | 3.65 | 4.24 | |
Debt/Assets |
25.65% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.43 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 0.98 | 0.72 | 0.54 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(2,126.27) | — | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.17) | (1.08) | (0.99) | (0.76) | |
Cash per Share |
8.13 | 4.31 | 5.22 | 6.26 | |
Shareholders Equity per Share |
4.99 | 3.51 | 4.34 | 5.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.99 | 3.51 | 4.34 | 5.67 | |
Free Cash Flow |
(138.19) | (125.17) | (113.98) | (85.29) | |
Working Capital |
839.10 | 407.91 | 501.88 | 638.93 | |
Net Current Asset Value |
584.43 | 403.98 | 501.88 | 638.93 | |
| Other line items | |||||
Quick Ratio |
7.17 | 4.57 | 5.67 | 9.21 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.17) | (1.08) | (0.99) | (0.76) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
43.27 | 37.25 | 37.44 | 31.53 | |
Average Assets |
858.29 | 674.87 | 737.62 | 812.03 | |
Average Common Equity |
650.82 | 601.89 | 674.42 | 759.67 |
Columns are period end dates · fundamentals updated 2 Nov 2026